Lineage Cell Therapeutics, Inc. Proceeds from Sale of Equity Method Investments
Lineage Cell Therapeutics, Inc. (LCTX) reported Proceeds from Sale of Equity Method Investments of $3.21 million for the 12-month period ending 2018-12-31, per its 10-K filed 2020-03-12.
Discontinued › Cash Flow › Investing Activities
us-gaap:ProceedsFromSaleOfEquityMethodInvestments · last filed 2020-03-12
- Lineage Cell Therapeutics, Inc. proceeds from sale of equity method investments for the quarter ending 2018-12-31 was $0.00.
- Lineage Cell Therapeutics, Inc. proceeds from sale of equity method investments for the quarter ending 2018-09-30 was $0.00.
- Lineage Cell Therapeutics, Inc. proceeds from sale of equity method investments for the quarter ending 2018-06-30 was $0.00.
- Lineage Cell Therapeutics, Inc. proceeds from sale of equity method investments for the quarter ending 2018-03-31 was $3.21M.
- Lineage Cell Therapeutics, Inc. proceeds from sale of equity method investments for fiscal 2018 was $3.21M.
- Lineage Cell Therapeutics, Inc. proceeds from sale of equity method investments for fiscal 2016 was $4.67M, a 13245.71% increase from fiscal 2015.
- Lineage Cell Therapeutics, Inc. proceeds from sale of equity method investments for fiscal 2015 was $35.00K.
- Lineage Cell Therapeutics, Inc. proceeds from sale of equity method investments for fiscal 2014 was $0.00.
| Period end | Proceeds from Sale of Equity Method Investments 3 month | Proceeds from Sale of Equity Method Investments 6 month | Proceeds from Sale of Equity Method Investments 9 month | Proceeds from Sale of Equity Method Investments 12 month |
|---|---|---|---|---|
| 2018-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2020-03-12 | $0.00 derived: sum of 2 quarters · filed 2020-03-12 | $0.00 derived: sum of 3 quarters · filed 2020-03-12 | $3.21M 10-K · filed 2020-03-12 |
| 2018-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2019-11-12 | $0.00 derived: sum of 2 quarters · filed 2019-11-12 | $3.21M 10-Q · filed 2019-11-12 | |
| 2018-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2019-08-08 | $3.21M 10-Q · filed 2019-08-08 | ||
| 2018-03-31 | $3.21M 10-Q · filed 2019-05-09 | |||
| 2016-12-31 | $4.67M 10-K · filed 2017-03-16 | |||
| 2015-12-31 | $35.00K 10-K · filed 2017-03-16 | |||
| 2014-12-31 | $0.00 10-K · filed 2017-03-16 | |||
| 2013-12-31 | $0.00 10-K · filed 2016-03-15 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Aligos Therapeutics, Inc. (ALGS) | United States | $0.238B | -0.47 |
| SUTRO BIOPHARMA, INC. (STRO) | United States | $0.260B | -3.05 |
| Protalix BioTherapeutics, Inc. (PLX) | $0.221B | 9.87 | |
| ANAVEX LIFE SCIENCES CORP. (AVXL) | United States | $0.218B | -18.37 |
| Alector, Inc. (ALEC) | United States | $0.213B | -1.90 |
| Invivyd, Inc. (IVVD) | United States | $0.270B | -2.42 |
| PALISADE BIO, INC. (PALI) | United States | $0.275B | -11.41 |
| Compass Therapeutics, Inc. (CMPX) | United States | $0.204B | -5.35 |
| Lexeo Therapeutics, Inc. (LXEO) | United States | $0.278B | -4.19 |
| FATE THERAPEUTICS INC (FATE) | United States | $0.280B | -2.51 |